The company has poor fundamentals for a short-term investment strategy.
According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Analysts covering this company mostly recommend stock overweighting or purchase.
The tendency within the weekly time frame is positive above the technical support level at 54.94 USD
Stock prices approach a strong long-term resistance in weekly data at USD 71.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 57.08 times its estimated earnings per share for the ongoing year.
The company is not the most generous with respect to shareholders' compensation.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.